E. Association, . The, . L. Of, and . Easl, Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, vol.50, issue.2, pp.227-269, 2009.

L. As and M. Bj, Chronic hepatitis B: update, Hepatology, vol.50, issue.3, pp.661-663, 2009.

C. Cj, Y. Hi, S. J. , J. Cl, Y. Sl et al., Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, Jama, vol.295, issue.1, pp.65-73, 2006.

L. Yf, S. J. , C. Wc, F. G. , L. Cz et al., Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, vol.351, issue.15, pp.1521-1552, 2004.

C. Tt, W. Liaw-yf, S. E. Ss, H. Kh, and L. Cl, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology

H. Sj, T. Nc, H. Ej, C. Tt, K. G. et al., Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years, Gastroenterology, vol.131, issue.6, pp.1743-51, 2006.

M. P. , L. Gk, F. P. Bonino-f, H. S. , and J. R. , Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, vol.351, issue.12, pp.1206-1223, 2004.

L. Gk, P. T. , L. Kx, M. P. , T. S. et al., Peginterferon Alfa-2a, lamivudine, and the combination for

L. Cl, D. J. , S. E. , L. Nw, A. M. et al., Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B, Clin Infect Dis, vol.36, issue.6, pp.687-96, 2003.

L. As, L. Cl, L. N. , Y. Gb, C. Zy et al., Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, vol.125, issue.6, pp.1714-1736, 2003.

M. P. , C. Tt, L. Sg, S. W. , T. M. et al., Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, Hepatology, vol.48, issue.3, pp.750-758, 2008.

L. Yf, G. E. , L. N. , Z. S. , W. Y. et al., 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B, Gastroenterology, vol.136, issue.2, pp.486-95, 2009.

C. Tt, L. Cl, K. Yoon-s, L. Ss, C. Hs et al., Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, vol.51, issue.2, pp.422-452

D. Marco, V. , M. A. , L. P. , A. P. et al., Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine, Hepatology, vol.348, issue.4, pp.883-91, 2004.
DOI : 10.1002/hep.20381

Y. Hj, L. Y. Hussain-m, W. Sn, F. Sk, and L. As, Evolution of multi-drug resistant hepatitis B virus during sequential therapy, Hepatology, vol.44, issue.3, pp.703-715, 2006.

V. S. , P. C. Villeneuve-jp, T. C. , and Z. F. , Selection of a multiple drug-resistant hepatitis B virus strain in a liver

V. S. , O. A. , P. C. , B. L. Villeneuve-jp, and T. C. , Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient, J Hepatol, vol.46, issue.3, pp.531-539, 2007.

R. Jg, D. K. , P. J. , Z. F. , S. T. et al., Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues, J Hepatol, vol.52, issue.4, pp.493-500

D. Van-bommel-f, W. H. Man-ra, D. K. , P. J. , and B. P. , Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues, Hepatology, vol.48, issue.1, pp.73-80
DOI : 10.1002/hep.23246

L. Yf, L. N. Kao-jh, P. T. , G. E. , and H. Kh, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatol Int, vol.2, issue.3, pp.263-83, 2008.

G. R. and M. Rh, Mutation rate of the hepadnavirus genome, Virology, vol.170, issue.2, pp.595-602, 1989.

S. M. , V. D. , P. Mc, B. A. Ippolito-g, and C. Mr, Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen, J Virol, vol.83, issue.4, pp.1718-1744, 2009.

Y. Mf, S. E. , H. Ck, Y. Hj, D. H. et al., Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy, Hepatology, vol.34, issue.4, pp.785-91, 2001.

K. Eb, D. Dt, H. Sh, J. Im, M. P. et al., A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update, Clin Gastroenterol Hepatol, vol.4, issue.8, pp.936-62, 2006.

K. Eb, Z. S. , K. Rs, D. Dt, E. et al., Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B, Clin Gastroenterol Hepatol, vol.5, issue.8, pp.890-897, 2007.

Y. Mf, F. Dy, W. Dk, Y. Jc, F. J. et al., Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

T. Dj, R. R. Baldick-cj, P. Ka, E. Bj, and F. J. , Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy, Hepatology, vol.49, issue.5, pp.1503-1517, 2009.

P. J. , D. M. , M. W. , L. M. Volz-t, and . Von, Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein, Nat Biotechnol, vol.26, issue.3, pp.335-376, 2008.